



Universiteit
Leiden
The Netherlands

Biomarkers in Duchenne and Becker muscular dystrophy

Velde, N.M. van de

Citation

Velde, N. M. van de. (2026, February 11). *Biomarkers in Duchenne and Becker muscular dystrophy*. Retrieved from <https://hdl.handle.net/1887/4291966>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4291966>

Note: To cite this publication please use the final published version (if applicable).





References

REFERENCES

1. Duchenne G.B.A. The Pathology of Paralysis with Muscular Degeneration (Paralysie Myosclerotique), or Paralysis with Apparent Hypertrophy. *Br Med J*. 1867;2(363):541-2.
2. Becker PE, Kiener F. [A new x-chromosomal muscular dystrophy]. *Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr*. 1955;193(4):427-48.
3. Hoffman EP, Brown RH, Jr., Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. *Cell*. 1987;51(6):919-28.
4. Kunkel LM, Hejtmanic JF, Caskey CT, Speer A, Monaco AP, Middlesworth W, et al. Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. *Nature*. 1986;322(6074):73-7.
5. Emery AE. The muscular dystrophies. *Lancet*. 2002;359(9307):687-95.
6. Darras BT, Miller DT, Urion DK. Dystrophinopathies in *GeneReviews®* (ed Pagon, R.A. et al.): Internet. Seattle (WA): University of Washington, 1993-2015; [Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1119/>].
7. Emery AE. Population frequencies of inherited neuromuscular diseases--a world survey. *Neuromuscular disorders : NMD*. 1991;1(1):19-29.
8. Ciafaloni E, Fox DJ, Pandya S, Westfield CP, Puzhankara S, Romitti PA, et al. Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). *The Journal of pediatrics*. 2009;155(3):380-5.
9. van Dommelen P, van Dijk O, de Wilde JA, Verkerk PH. Early developmental milestones in Duchenne muscular dystrophy. *Developmental medicine and child neurology*. 2020;62(10):1198-204.
10. Mercuri E, Bonnemann CG, Muntoni F. Muscular dystrophies. *Lancet*. 2019;394(10213):2025-38.
11. Flanigan KM. Duchenne and Becker muscular dystrophies. *Neurol Clin*. 2014;32(3):671-88, viii.
12. McDonald CM, Abresch RT, Carter GT, Fowler WM, Jr., Johnson ER, Kilmer DD, et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. *Am J Phys Med Rehabil*. 1995;74(5 Suppl):S70-92.
13. McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. *Lancet*. 2018;391(10119):451-61.
14. Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. *International journal of cardiology*. 1990;26(3):271-7.
15. Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. *Neuromuscular disorders : NMD*. 2014;24(6):482-91.
16. Bushby KM, Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. *J Neurol*. 1993;240(2):98-104.

17. Yazaki M, Yoshida K, Nakamura A, Koyama J, Nanba T, Ohori N, et al. Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years. *Eur Neurol.* 1999;42(3):145-9.
18. Heald A, Anderson LV, Bushby KM, Shaw PJ. Becker muscular dystrophy with onset after 60 years. *Neurology.* 1994;44(12):2388-90.
19. Palmucci L, Doriguzzi C, Mongini T, Restagno G, Chiado-Piat L, Maniscalco M. Unusual expression and very mild course of Xp21 muscular dystrophy (Becker type) in a 60-year-old man with 26 percent deletion of the dystrophin gene. *Neurology.* 1994;44(3 Pt 1):541-3.
20. Melacini P, Fanin M, Danieli GA, Villanova C, Martinello F, Miorin M, et al. Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy. *Circulation.* 1996;94(12):3168-75.
21. Finsterer J, Stollberger C. Cardiac involvement in Becker muscular dystrophy. *Can J Cardiol.* 2008;24(10):786-92.
22. Kirchmann C, Kececioğlu D, Korinthenberg R, Dittrich S. Echocardiographic and electrocardiographic findings of cardiomyopathy in Duchenne and Becker-Kiener muscular dystrophies. *Pediatric cardiology.* 2005;26(1):66-72.
23. Yilmaz A, Gdynia HJ, Baccouche H, Mahrholdt H, Meinhardt G, Basso C, et al. Cardiac involvement in patients with Becker muscular dystrophy: new diagnostic and pathophysiological insights by a CMR approach. *J Cardiovasc Magn Reson.* 2008;10:50.
24. Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. *Hum Mutat.* 2015;36(4):395-402.
25. Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. *Muscle & nerve.* 2006;34(2):135-44.
26. Tuffery-Giraud S, Beroud C, Leturcq F, Yaou RB, Hamroun D, Michel-Calemard L, et al. Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. *Hum Mutat.* 2009;30(6):934-45.
27. Campbell KP, Kahl SD. Association of dystrophin and an integral membrane glycoprotein. *Nature.* 1989;338(6212):259-62.
28. Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycoprotein complex. *Cell.* 1991;66(6):1121-31.
29. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, Campbell KP. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. *Nature.* 1992;355(6362):696-702.
30. Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. *Nat Rev Dis Primers.* 2021;7(1):13.

31. Clafin DR, Brooks SV. Direct observation of failing fibers in muscles of dystrophic mice provides mechanistic insight into muscular dystrophy. *Am J Physiol Cell Physiol.* 2008;294(2):C651-8.
32. Meyers TA, Townsend D. Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy. *Int J Mol Sci.* 2019;20(17).
33. Frankel KA, Rosser RJ. The pathology of the heart in progressive muscular dystrophy: epimycocardial fibrosis. *Hum Pathol.* 1976;7(4):375-86.
34. Moriuchi T, Kagawa N, Mukoyama M, Hizawa K. Autopsy analyses of the muscular dystrophies. *Tokushima J Exp Med.* 1993;40(1-2):83-93.
35. Kamdar F, Garry DJ. Dystrophin-Deficient Cardiomyopathy. *J Am Coll Cardiol.* 2016;67(21):2533-46.
36. Kamogawa Y, Biro S, Maeda M, Setoguchi M, Hirakawa T, Yoshida H, et al. Dystrophin-deficient myocardium is vulnerable to pressure overload in vivo. *Cardiovasc Res.* 2001;50(3):509-15.
37. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. *Lancet Neurol.* 2010;9(1):77-93.
38. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. *Lancet Neurol.* 2010;9(2):177-89.
39. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. *Lancet Neurol.* 2018;17(3):251-67.
40. Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. *Lancet Neurol.* 2018;17(4):347-61.
41. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. *Lancet Neurol.* 2018;17(5):445-55.
42. Griggs RC, Moxley RT, 3rd, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. *Arch Neurol.* 1991;48(4):383-8.
43. Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. *Cochrane Database Syst Rev.* 2016(5):CD003725.
44. Gloss D, Moxley RT, 3rd, Ashwal S, Oskoui M. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology.* 2016;86(5):465-72.

45. Viollet L, Thrush PT, Flanigan KM, Mendell JR, Allen HD. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. *The American journal of cardiology*. 2012;110(1):98-102.
46. Feingold B, Mahle WT, Auerbach S, Clemens P, Domenighetti AA, Jefferies JL, et al. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. *Circulation*. 2017;136(13):e200-e31.
47. Broomfield J, Hill M, Guglieri M, Crowther M, Abrams K. Life Expectancy in Duchenne Muscular Dystrophy: Reproduced Individual Patient Data Meta-analysis. *Neurology*. 2021;97(23):e2304-e14.
48. Markati T, Oskoui M, Farrar MA, Duong T, Goemans N, Servais L. Emerging therapies for Duchenne muscular dystrophy. *Lancet Neurol*. 2022;21(9):814-29.
49. Mullard A. FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections. *Nat Rev Drug Discov*. 2023.
50. Syed YY. Eteplirsen: First Global Approval. *Drugs*. 2016;76(17):1699-704.
51. Ryan NJ. Ataluren: first global approval. *Drugs*. 2014;74(14):1709-14.
52. European Medicines Agency. EMA confirms recommendation for non-renewal of authorisation of Duchenne muscular dystrophy medicine Translarna 2024 [Available from: <https://www.ema.europa.eu/en/news/ema-confirms-recommendation-non-renewal-authorisation-duchenne-muscular-dystrophy-medicine-translarna>].
53. Dugar S, Villarreal F, Hollinger FH, Mahajan D, Ramirez-Sanchez I, Moreno-Ulloa A, et al. 11-beta-hydroxysterols as possible endogenous stimulators of mitochondrial biogenesis as inferred from epicatechin molecular mimicry. *Pharmacol Res*. 2020;151:104540.
54. Ramirez-Sanchez I, De los Santos S, Gonzalez-Basurto S, Canto P, Mendoza-Lorenzo P, Palma-Flores C, et al. (-)-Epicatechin improves mitochondrial-related protein levels and ameliorates oxidative stress in dystrophic delta-sarcoglycan null mouse striated muscle. *FEBS J*. 2014;281(24):5567-80.
55. McDonald CM, Ramirez-Sanchez I, Oskarsson B, Joyce N, Aguilar C, Nicorici A, et al. (-)-Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with Becker muscular dystrophy. *Muscle & nerve*. 2021;63(2):239-49.
56. Edgewise Therapeutics Inc. A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults 2020 [Available from: <https://clinicaltrials.gov/ct2/show/NCT04585464>].
57. Consalvi S, Mozzetta C, Bettica P, Germani M, Fiorentini F, Del Bene F, et al. Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat. *Mol Med*. 2013;19:79-87.
58. Licandro SA, Crippa L, Pomarico R, Perego R, Fossati G, Leoni F, et al. The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene. *Skelet Muscle*. 2021;11(1):19.

REFERENCES

59. Italmarmaco. Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dystrophy 2017 [Available from: <https://clinicaltrials.gov/ct2/show/NCT03238235?term=givinostat&draw=2&rank=3>].
60. Comi GP, Niks EH, Cinnante CM, Kan HE, Vandenborne K, Willcocks RJ, et al. Characterization of patients with Becker muscular dystrophy by histology, magnetic resonance imaging, function, and strength assessments. *Muscle & nerve*. 2022;65(3):326-33.
61. Comi GP, Niks EH, Vandenborne K, Cinnante CM, Kan HE, Willcocks RJ, et al. Givinostat for Becker muscular dystrophy: A randomized, placebo-controlled, double-blind study. *Front Neurol*. 2023;14:1095121.
62. Goemans N, Klingels K, van den Hauwe M, Boons S, Verstraete L, Peeters C, et al. Six-minute walk test: reference values and prediction equation in healthy boys aged 5 to 12 years. *PLoS One*. 2013;8(12):e84120.
63. Ricotti V, Ridout DA, Pane M, Main M, Mayhew A, Mercuri E, et al. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. *Journal of neurology, neurosurgery, and psychiatry*. 2016;87(2):149-55.
64. Mazzone ES, Pane M, Sormani MP, Scalise R, Berardinelli A, Messina S, et al. 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. *PLoS One*. 2013;8(1):e52512.
65. Pane M, Mazzone ES, Sormani MP, Messina S, Vita GL, Fanelli L, et al. 6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes. *PLoS One*. 2014;9(1):e83400.
66. McDonald CM, Henricson EK, Abresch RT, Florence JM, Eagle M, Gappmaier E, et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. *Muscle & nerve*. 2013;48(3):343-56.
67. Goemans N, Vanden Hauwe M, Signorovitch J, Swallow E, Song J, Collaborative Trajectory Analysis P. Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy. *PLoS One*. 2016;11(10):e0164684.
68. Mercuri E, Signorovitch JE, Swallow E, Song J, Ward SJ, Group DMDI, et al. Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy. *Neuromuscular disorders : NMD*. 2016;26(9):576-83.
69. Kirschner J, Schessl J, Schara U, Reitter B, Stettner GM, Hobbiebrunken E, et al. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial. *Lancet Neurol*. 2010;9(11):1053-9.
70. U.S. Department of Health and Human Services Food and Drug Administration. Real-world evidence program 2018 [Available from: <https://www.fda.gov/media/120060/download>].
71. European Medicines Agency. Update on Real-World Evidence and DARWIN EU 2021 [Available from: https://www.ema.europa.eu/en/documents/presentation/update-real-world-evidence-darwin-eu-gianmario-candore_en.pdf].

72. Goemans N, Signorovitch J, Sajeev G, Yao Z, Gordish-Dressman H, McDonald CM, et al. Suitability of external controls for drug evaluation in Duchenne muscular dystrophy. *Neurology*. 2020;95(10):e1381-e91.
73. Muntoni F, Signorovitch J, Sajeev G, Goemans N, Wong B, Tian C, et al. Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls. *Neuromuscular disorders : NMD*. 2022;32(4):271-83.
74. Muntoni F, Signorovitch J, Sajeev G, Lane H, Jenkins M, Dieye I, et al. DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials. *Neurology*. 2023;100(15):e1540-e54.
75. van den Bergen JC, Ginjaar HB, van Essen AJ, Pangalila R, de Groot IJ, Wijkstra PJ, et al. Forty-Five Years of Duchenne Muscular Dystrophy in The Netherlands. *J Neuromuscul Dis*. 2014;1(1):99-109.
76. ProMISe. [Available from: <https://www.msbi.nl/promise/>].
77. U.S. Food and Drug Administration - National Institutes of Health Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]: Silver Spring (MD): Food and Drug Administration (US); Co-published by National Institutes of Health (US), Bethesda (MD); 2016-.
78. U.S. Department of Health and Human Services Food and Drug Administration. Context of Use for a biomarker 2021 [Available from: <https://www.fda.gov/drugs/biomarker-qualification-program/context-use>].
79. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;62(16):e147-239.
80. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014;311(5):507-20.
81. Flanigan KM, Ceco E, Lamar KM, Kaminoh Y, Dunn DM, Mendell JR, et al. LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. *Ann Neurol*. 2013;73(4):481-8.
82. Al-Khalili Szigyarto C. Duchenne Muscular Dystrophy: recent advances in protein biomarkers and the clinical application. *Expert Rev Proteomics*. 2020;17(5):365-75.
83. Houwen-van Opstal SLS, Rodwell L, Bot D, Daalmeyer A, Willemsen M, Niks EH, et al. BMI-z scores of boys with Duchenne muscular dystrophy already begin to increase before losing ambulation: a longitudinal exploration of BMI, corticosteroids and caloric intake. *Neuromuscul Disord*. 2022;32(3):236-44.
84. Davidson ZE, Ryan MM, Kornberg AJ, Sinclair K, Cairns A, Walker KZ, et al. Observations of body mass index in Duchenne muscular dystrophy: a longitudinal study. *Eur J Clin Nutr*. 2014;68(8):892-7.

REFERENCES

85. Tops LF, Delgado V, Marsan NA, Bax JJ. Myocardial strain to detect subtle left ventricular systolic dysfunction. *European journal of heart failure*. 2017;19(3):307-13.
86. Yilmaz A, Sechtem U. Cardiac involvement in muscular dystrophy: advances in diagnosis and therapy. *Heart*. 2012;98(5):420-9.
87. McNally EM. New approaches in the therapy of cardiomyopathy in muscular dystrophy. *Annu Rev Med*. 2007;58:75-88.
88. Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2004;43(12):2260-4.
89. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2015;16(3):233-70.
90. Cirino RHD, Scola RH, Ducci RD, Camarozano AC, Kay CSK, Lorenzoni PJ, et al. Evaluation of Left-Sided Heart Chambers With Novel Echocardiographic Techniques in Men With Duchenne or Becker Muscular Dystrophy. *The American journal of cardiology*. 2019;123(6):972-8.
91. Taqatqa A, Bokowski J, Al-Kubaisi M, Khalil A, Miranda C, Alaksham H, et al. The Use of Speckle Tracking Echocardiography for Early Detection of Myocardial Dysfunction in Patients with Duchenne Muscular Dystrophy. *Pediatric cardiology*. 2016;37(8):1422-8.
92. Spurney CF, McCaffrey FM, Cnaan A, Morgenroth LP, Ghelani SJ, Gordish-Dressman H, et al. Feasibility and Reproducibility of Echocardiographic Measures in Children with Muscular Dystrophies. *J Am Soc Echocardiogr*. 2015;28(8):999-1008.
93. Bonanno S, Marcuzzo S, Malacarne C, Giagnorio E, Masson R, Zanin R, et al. Circulating MyomiRs as Potential Biomarkers to Monitor Response to Nusinersen in Pediatric SMA Patients. *Biomedicines*. 2020;8(2).
94. Nadarajah VD, van Putten M, Chaouch A, Garrood P, Straub V, Lochmuller H, et al. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). *Neuromuscular disorders : NMD*. 2011;21(8):569-78.
95. Loubakos A, Yau N, de Bruijn P, Hiller M, Kozaczynska K, Jean-Baptiste R, et al. Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne. *Sci Rep*. 2017;7(1):17888.
96. Spitali P, Hettne K, Tsonaka R, Sabir E, Seyer A, Hemerik JBA, et al. Cross-sectional serum metabolomic study of multiple forms of muscular dystrophy. *J Cell Mol Med*. 2018;22(4):2442-8.
97. Boca SM, Nishida M, Harris M, Rao S, Cheema AK, Gill K, et al. Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study. *PLoS One*. 2016;11(4):e0153461.
98. Burch PM, Pogoryelova O, Palandra J, Goldstein R, Bennett D, Fitz L, et al. Reduced serum myostatin concentrations associated with genetic muscle disease progression. *J Neurol*. 2017;264(3):541-53.

99. Mariot V, Joubert R, Hourde C, Feasson L, Hanna M, Muntoni F, et al. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. *Nat Commun.* 2017;8(1):1859.
100. Anaya-Segura MA, Garcia-Martinez FA, Montes-Almanza LA, Diaz BG, Avila-Ramirez G, Alvarez-Maya I, et al. Non-Invasive Biomarkers for Duchenne Muscular Dystrophy and Carrier Detection. *Molecules.* 2015;20(6):11154-72.
101. Burakiewicz J, Sinclair CDJ, Fischer D, Walter GA, Kan HE, Hollingsworth KG. Quantifying fat replacement of muscle by quantitative MRI in muscular dystrophy. *J Neurol.* 2017;264(10):2053-67.
102. Forbes SC, Walter GA, Rooney WD, Wang DJ, DeVos S, Pollaro J, et al. Skeletal muscles of ambulant children with Duchenne muscular dystrophy: validation of multicenter study of evaluation with MR imaging and MR spectroscopy. *Radiology.* 2013;269(1):198-207.
103. Willis TA, Hollingsworth KG, Coombs A, Sveen ML, Andersen S, Stojkovic T, et al. Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: a multicentre longitudinal study. *PLoS One.* 2013;8(8):e70993.
104. Willcocks RJ, Rooney WD, Triplett WT, Forbes SC, Lott DJ, Senesac CR, et al. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort. *Ann Neurol.* 2016;79(4):535-47.
105. Carlier PG. Global T2 versus water T2 in NMR imaging of fatty infiltrated muscles: different methodology, different information and different implications. *Neuromuscular disorders : NMD.* 2014;24(5):390-2.
106. Keene KR, Beenakker JM, Hooijmans MT, Naarding KJ, Niks EH, Otto LAM, et al. T2 relaxation-time mapping in healthy and diseased skeletal muscle using extended phase graph algorithms. *Magn Reson Med.* 2020;84(5):2656-70.
107. Barnard AM, Willcocks RJ, Finanger EL, Daniels MJ, Triplett WT, Rooney WD, et al. Skeletal muscle magnetic resonance biomarkers correlate with function and sentinel events in Duchenne muscular dystrophy. *PLoS One.* 2018;13(3):e0194283.
108. Fischmann A, Hafner P, Fasler S, Gloor M, Bieri O, Studler U, et al. Quantitative MRI can detect subclinical disease progression in muscular dystrophy. *J Neurol.* 2012;259(8):1648-54.
109. Bonati U, Hafner P, Schadelin S, Schmid M, Naduvilekoot Devasia A, Schroeder J, et al. Quantitative muscle MRI: A powerful surrogate outcome measure in Duchenne muscular dystrophy. *Neuromuscular disorders : NMD.* 2015;25(9):679-85.
110. Naarding KJ, Reyngoudt H, van Zwet EW, Hooijmans MT, Tian C, Rybalsky I, et al. MRI vastus lateralis fat fraction predicts loss of ambulation in Duchenne muscular dystrophy. *Neurology.* 2020;94(13):e1386-e94.
111. Barnard AM, Willcocks RJ, Triplett WT, Forbes SC, Daniels MJ, Chakraborty S, et al. MR biomarkers predict clinical function in Duchenne muscular dystrophy. *Neurology.* 2020;94(9):e897-e909.
112. Nagy S, Schadelin S, Hafner P, Bonati U, Scherrer D, Ebi S, et al. Longitudinal reliability of outcome measures in patients with Duchenne muscular dystrophy. *Muscle & nerve.* 2020;61(1):63-8.

REFERENCES

113. Fischer D, Hafner P, Rubino D, Schmid M, Neuhaus C, Jung H, et al. The 6-minute walk test, motor function measure and quantitative thigh muscle MRI in Becker muscular dystrophy: A cross-sectional study. *Neuromuscular disorders : NMD*. 2016;26(7):414-22.
114. Barp A, Bello L, Caumo L, Campadello P, Semplicini C, Lazzarotto A, et al. Muscle MRI and functional outcome measures in Becker muscular dystrophy. *Sci Rep*. 2017;7(1):16060.
115. Maggi L, Moscatelli M, Frangiamore R, Mazzi F, Verri M, De Luca A, et al. Quantitative Muscle MRI Protocol as Possible Biomarker in Becker Muscular Dystrophy. *Clin Neuroradiol*. 2021;31(1):257-66.
116. Tasca G, Iannaccone E, Monforte M, Masciullo M, Bianco F, Laschena F, et al. Muscle MRI in Becker muscular dystrophy. *Neuromuscular disorders : NMD*. 2012;22 Suppl 2:S100-6.
117. Sheikh AM, Rudolf K, Witting N, Vissing J. Quantitative Muscle MRI as Outcome Measure in Patients With Becker Muscular Dystrophy-A 1-Year Follow-Up Study. *Front Neurol*. 2020;11:613489.
118. Kariyawasam D, D'Silva A, Mowat D, Russell J, Sampaio H, Jones K, et al. Incidence of Duchenne muscular dystrophy in the modern era; an Australian study. *Eur J Hum Genet*. 2022;30(12):1398-404.
119. Forrest SM, Cross GS, Flint T, Speer A, Robson KJ, Davies KE. Further studies of gene deletions that cause Duchenne and Becker muscular dystrophies. *Genomics*. 1988;2(2):109-14.
120. Beekman C, Janson AA, Baghat A, van Deutekom JC, Datson NA. Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy. *Plos One*. 2018;13(4).
121. Landfeldt E, Lindberg C, Sejersen T. Improvements in health status and utility associated with ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy. *Muscle Nerve*. 2020;61(3):363-8.
122. Bushby KM, Gardner-Medwin D, Nicholson LV, Johnson MA, Haggerty ID, Cleghorn NJ, et al. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities. *J Neurol*. 1993;240(2):105-12.
123. Grain L, Cortina-Borja M, Forfar C, Hilton-Jones D, Hopkin J, Burch M. Cardiac abnormalities and skeletal muscle weakness in carriers of Duchenne and Becker muscular dystrophies and controls. *Neuromuscul Disord*. 2001;11(2):186-91.
124. Hoogerwaard EM, van der Wouw PA, Wilde AA, Bakker E, Ippel PF, Oosterwijk JC, et al. Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. *Neuromuscul Disord*. 1999;9(5):347-51.
125. Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. *Nat Rev Neurol*. 2019;15(7):373-86.
126. Straub V, Guglieri M. An update on Becker muscular dystrophy. *Curr Opin Neurol*. 2023;36(5):450-4.

127. Brogna C, Coratti G, Pane M, Ricotti V, Messina S, D'Amico A, et al. Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. *PLoS One*. 2019;14(6):e0218683.
128. Pane M, Mazzone ES, Sivo S, Sormani MP, Messina S, D'Amico A, et al. Correction: Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes. *PLoS One*. 2015;10(12):e0144079.
129. Brogna C, Coratt G, Pane M, Ricotti V, Messina S, D'Amico A, et al. Correction: Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. *PLoS One*. 2019;14(7):e0220714.
130. Naarding KJ, Doorenweerd N, Koeks Z, Hendriksen RGF, Chotkan KA, Krom YD, et al. Decision-Making And Selection Bias in Four Observational Studies on Duchenne and Becker Muscular Dystrophy. *J Neuromuscul Dis*. 2020;7(4):433-42.
131. European Commision. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing directive 95/46/EC (General data protection regulation). *Official Journal of the European Union*. 2016:1-88.
132. Manniën JMJ, Ledderhof T, Verspaget HW, Snijder RR, Flikkenschild EF, Scherrenburg NPCv, et al. The Parelsnoer Institute: A National Network of Standardized Clinical Biobanks in the Netherlands. *Human Bioresources Papers*. 2017;4:3.
133. Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, et al. The FAIR Guiding Principles for scientific data management and stewardship. *Sci Data*. 2016;3:160018.
134. TREAT-NMD. Duchenne Muscular Dystrophy (DMD) Core Dataset 2021 [Available from: <https://treat-nmd.org/patient-registries/treat-nmd-core-datasets/treat-nmd-dmd-core-dataset/#1614077124057-8b1cb7ef-a7a1>].
135. Castor EDC. Castor Electronic Data Capture 2019 [Available from: <https://www.castoredc.com/>].
136. Webpage of Dutch Dystrophinopathy Database for new registrants [Available from: <https://duchenneexpertisecentrum.nl/research/dutch-dystrofinopathy-database-een-nationaal-register-voor-duchenne-en-becker/>].
137. van den Biggelaar RJM, Hazenberg A, Cobben NAM, Gommers D, Gaytant MA, Wijkstra PJ. Home mechanical ventilation: the Dutch approach. *Pulmonology*. 2022;28(2):99-104.
138. Krom YDS, R.R.; Niks, E.H. Dutch Dystrophinopathy Database- FAIR from the start 2024 [Available from: <https://duchenneexpertisecentrum.nl/dutch-dystrofinopathy-dataset/>].
139. Koeks Z, Hellebrekers DMJ, van de Velde NM, Alleman I, Spitali P, van Duyvenvoorde HA, et al. The neurocognitive profile of adults with Becker muscular dystrophy in the Netherlands. *J Neuromuscul Dis*. 2022;9(4):543-53.
140. Houwen-van Opstal SLS, Heutinck L, Jansen M, Krom YD, Cup EHC, Hendriksen JGM, et al. Occurrence of symptoms in different stages of Duchenne muscular dystrophy and their impact on social participation. *Muscle Nerve*. 2021;64(6):701-9.

REFERENCES

141. Heutinck L, Houwen-van Opstal SLS, Krom YD, Niks EH, Verschuuren J, Jansen M, et al. Compliance to DMD Care Considerations in the Netherlands. *J Neuromuscul Dis.* 2021;8(6):927-38.
142. Clinical research: web page of Duchenne Center Netherlands [Available from: <https://duchenneexpertisecentrum.nl/research/>].
143. Feedback to patients: web page of Duchenne Center Netherlands [Available from: <https://duchenneexpertisecentrum.nl/passende-zorg/patienten/landelijke-registratie/>].
144. Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifiro G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. *Orphanet J Rare Dis.* 2020;15(1):141.
145. van Engelen BG, van Veenendaal H, van Doorn PA, Faber CG, van der Hoeven JH, Janssen NG, et al. The Dutch neuromuscular database CRAMP (Computer Registry of All Myopathies and Polyneuropathies): development and preliminary data. *Neuromuscul Disord.* 2007;17(1):33-7.
146. Bayat F, Sarmiento IG, Ahmadian N, Dehghani Z. Iranian Registry of Duchenne and Becker Muscular Dystrophies: Characterization and Preliminary Data. *J Neuromuscul Dis.* 2021;8(2):251-9.
147. Nakamura H, Kimura E, Mori-Yoshimura M, Komaki H, Matsuda Y, Goto K, et al. Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy). *Orphanet J Rare Dis.* 2013;8:60.
148. Hodgkinson V, Lounsberry J, M'Dahoma S, Russell A, Jewett G, Benstead T, et al. The Canadian Neuromuscular Disease Registry 2010-2019: A Decade of Facilitating Clinical Research Through a Nationwide, Pan-Neuromuscular Disease Registry. *J Neuromuscul Dis.* 2021;8(1):53-61.
149. Neri M, Rossi R, Trabanelli C, Mauro A, Selvatici R, Falzarano MS, et al. The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study. *Front Genet.* 2020;11:131.
150. Selvatici R, Rossi R, Fortunato F, Trabanelli C, Sifi Y, Margutti A, et al. Ethnicity-related DMD Genotype Landscapes in European and Non-European Countries. *Neurol Genet.* 2021;7(1):e536.
151. Brabec P, Vondracek P, Klimes D, Baumeister S, Lochmuller H, Pavlik T, et al. Characterization of the DMD/BMD patient population in Czech Republic and Slovakia using an innovative registry approach. *Neuromuscul Disord.* 2009;19(4):250-4.
152. Ligon AH, Kashork CD, Richards CS, Shaffer LG. Identification of female carriers for Duchenne and Becker muscular dystrophies using a FISH-based approach. *Eur J Hum Genet.* 2000;8(4):293-8.
153. Sarkozy A, Quinlivan R, Bourke JP, Ferlini A, Group ErWS. 263rd ENMC International Workshop: Focus on female carriers of dystrophinopathy: refining recommendations for prevention, diagnosis, surveillance, and treatment. Hoofddorp, The Netherlands, 13-15 May 2022. *Neuromuscular disorders : NMD.* 2023;33(3):274-84.

154. Kaliyaperumal R, Wilkinson MD, Moreno PA, Benis N, Cornet R, Dos Santos Vieira B, et al. Semantic modelling of common data elements for rare disease registries, and a prototype workflow for their deployment over registry data. *J Biomed Semantics*. 2022;13(1):9.
155. European Union. Art. 4 GDPR Definitions 2018 [Available from: <https://gdpr.eu/article-4-definitions/>].
156. Dos Santos Vieira B, Bernabe CH, Zhang S, Abaza H, Benis N, Camara A, et al. Towards FAIRification of sensitive and fragmented rare disease patient data: challenges and solutions in European reference network registries. *Orphanet J Rare Dis*. 2022;17(1):436.
157. Atalaia A, Wandrei D, Lalout N, Thompson R, Tassoni A, t Hoen PAC, et al. EURO-NMD registry: federated FAIR infrastructure, innovative technologies and concepts of a patient-centred registry for rare neuromuscular disorders. *Orphanet J Rare Dis*. 2024;19(1):66.
158. Web page of Duchenne Data Platform [Available from: <https://duchenne.nl/duchenne-data-platform-english/>].
159. Rybakova IN, Patel JR, Ervasti JM. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. *The Journal of cell biology*. 2000;150(5):1209-14.
160. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. *Neuromuscul Disord*. 2002;12(10):926-9.
161. Kulsum-Meccì N, Goss C, Kozel BA, Garbutt JM, Schechtman KB, Dharnidharka VR. Effects of Obesity and Hypertension on Pulse Wave Velocity in Children. *Journal of clinical hypertension*. 2016.
162. Wohlfahrt P, Redfield MM, Melenovsky V, Lopez-Jimenez F, Rodeheffer RJ, Borlaug BA. Impact of chronic changes in arterial compliance and resistance on left ventricular ageing in humans. *European journal of heart failure*. 2015;17(1):27-34.
163. Martigne L, Salleron J, Mayer M, Cuisset JM, Carpentier A, Neve V, et al. Natural evolution of weight status in Duchenne muscular dystrophy: a retrospective audit. *Br J Nutr*. 2011;105(10):1486-91.
164. Lamb MM, West NA, Ouyang L, Yang M, Weitzkamp D, James K, et al. Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy. *The Journal of pediatrics*. 2016;173:207-13 e3.
165. Dusenbery SM, Lunze FI, Jerosch-Herold M, Geva T, Newburger JW, Colan SD, et al. Left Ventricular Strain and Myocardial Fibrosis in Congenital Aortic Stenosis. *The American journal of cardiology*. 2015;116(8):1257-62.
166. Barbosa JA, Mota CC, Simoes ESAC, Nunes Mdo C, Barbosa MM. Assessing pre-clinical ventricular dysfunction in obese children and adolescents: the value of speckle tracking imaging. *European heart journal cardiovascular Imaging*. 2013;14(9):882-9.
167. Gauld LM, Kappers J, Carlin JB, Robertson CF. Height prediction from ulna length. *Developmental medicine and child neurology*. 2004;46(7):475-80.

168. National High Blood Pressure Education Program Working Group on High Blood Pressure in C, Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics*. 2004;114(2 Suppl 4th Report):555-76.
169. Centers. For Disease Control and Prevention. CDC growth charts [online]. [http://www.cdc.gov/growthcharts/ Default.htm](http://www.cdc.gov/growthcharts/Default.htm). 2000.
170. Lopez L, Colan SD, Frommelt PC, Ensing GJ, Kendall K, Younoszai AK, et al. Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. *J Am Soc Echocardiogr*. 2010;23(5):465-95; quiz 576-7.
171. Levy PT, Machevsky A, Sanchez AA, Patel MD, Rogal S, Fowler S, et al. Reference Ranges of Left Ventricular Strain Measures by Two-Dimensional Speckle-Tracking Echocardiography in Children: A Systematic Review and Meta-Analysis. *J Am Soc Echocardiogr*. 2016;29(3):209-25 e6.
172. Wong BL, Rybalsky I, Shellenbarger KC, Tian C, McMahon MA, Rutter MM, et al. Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment. *The Journal of pediatrics*. 2016.
173. Ricotti V, Ridout DA, Scott E, Quinlivan R, Robb SA, Manzur AY, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. *Journal of neurology, neurosurgery, and psychiatry*. 2013;84(6):698-705.
174. Braat E, Hoste L, De Waele L, Gheysens O, Vermeersch P, Goffin K, et al. Renal function in children and adolescents with Duchenne muscular dystrophy. *Neuromuscular disorders : NMD*. 2015;25(5):381-7.
175. Masood SA, Kazmouz S, Heydemann P, Li H, Kenny D. Under-recognition of Low Blood Pressure Readings in Patients with Duchenne Muscular Dystrophy. *Pediatric cardiology*. 2015;36(7):1489-94.
176. Scholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. *Can J Cardiol*. 2000;16(4):505-11.
177. Bello L, Gordish-Dressman H, Morgenroth LP, Henricson EK, Duong T, Hoffman EP, et al. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. *Neurology*. 2015;85(12):1048-55.
178. Barber BJ, Andrews JG, Lu Z, West NA, Meaney FJ, Price ET, et al. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy. *The Journal of pediatrics*. 2013;163(4):1080-4 e1.
179. Markham LW, Kinnett K, Wong BL, Woodrow Benson D, Cripe LH. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. *Neuromuscul Disord*. 2008;18(5):365-70.
180. Lanza GA, Dello Russo A, Giglio V, De Luca L, Messano L, Santini C, et al. Impairment of cardiac autonomic function in patients with Duchenne muscular dystrophy: relationship to myocardial and respiratory function. *Am Heart J*. 2001;141(5):808-12.

181. Loufrani L, Levy BI, Henrion D. Defect in microvascular adaptation to chronic changes in blood flow in mice lacking the gene encoding for dystrophin. *Circulation research*. 2002;91(12):1183-9.
182. Sander M, Chavoshan B, Harris SA, Lannaccone ST, Stull JT, Thomas GD, et al. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. *Proc Natl Acad Sci USA*. 2000;97(25):13818-23.
183. Kosmala W, Plaksej R, Strotmann JM, Weigel C, Herrmann S, Niemann M, et al. Progression of left ventricular functional abnormalities in hypertensive patients with heart failure: an ultrasonic two-dimensional speckle tracking study. *J Am Soc Echocardiogr*. 2008;21(12):1309-17.
184. Duboc D, Meune C, Pierre B, Wahbi K, Eymard B, Toutain A, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. *Am Heart J*. 2007;154(3):596-602.
185. Ramaciotti C, Heistein LC, Coursey M, Lemler MS, Eapen RS, Lannaccone ST, et al. Left ventricular function and response to enalapril in patients with duchenne muscular dystrophy during the second decade of life. *The American journal of cardiology*. 2006;98(6):825-7.
186. Munthali RJ, Kagura J, Lombard Z, Norris SA. Childhood adiposity trajectories are associated with late adolescent blood pressure: birth to twenty cohort. *BMC public health*. 2016;16:665.
187. Di Salvo G, Pacileo G, Del Giudice EM, Natale F, Limongelli G, Verrengia M, et al. Abnormal myocardial deformation properties in obese, non-hypertensive children: an ambulatory blood pressure monitoring, standard echocardiographic, and strain rate imaging study. *European heart journal*. 2006;27(22):2689-95.
188. Koopman LP, McCrindle BW, Slorach C, Chahal N, Hui W, Sarkola T, et al. Interaction between myocardial and vascular changes in obese children: a pilot study. *J Am Soc Echocardiogr*. 2012;25(4):401-10 e1.
189. Mangner N, Scheuermann K, Winzer E, Wagner I, Hoellriegel R, Sandri M, et al. Childhood obesity: impact on cardiac geometry and function. *JACC Cardiovascular imaging*. 2014;7(12):1198-205.
190. Joyce E, Ninaber MK, Katsanos S, Debonnaire P, Kamperidis V, Bax JJ, et al. Subclinical left ventricular dysfunction by echocardiographic speckle-tracking strain analysis relates to outcome in sarcoidosis. *Eur J Heart Fail*. 2015;17(1):51-62.
191. Gegenava T, Gegenava M, Steup-Beekman GM, Huizinga TWJ, Bax JJ, Delgado V, et al. Left Ventricular Systolic Function in Patients with Systemic Lupus Erythematosus and Its Association with Cardiovascular Events. *J Am Soc Echocardiogr*. 2020;33(9):1116-22.
192. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. *Muscle & nerve*. 2010;41(4):500-10.
193. Mazzone E, Martinelli D, Berardinelli A, Messina S, D'Amico A, Vasco G, et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. *Neuromuscular disorders : NMD*. 2010;20(11):712-6.

194. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28(1):1-39 e14.
195. Ajmone Marsan N, Michalski B, Cameli M, Podlesnikar T, Manka R, Sitges M, et al. EACVI survey on standardization of cardiac chambers quantification by transthoracic echocardiography. *Eur Heart J Cardiovasc Imaging*. 2020;21(2):119-23.
196. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. *J Am Soc Echocardiogr*. 2013;26(5):493-8.
197. Morrow JM, Sinclair CD, Fischmann A, Machado PM, Reilly MM, Yousry TA, et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. *Lancet Neurol*. 2016;15(1):65-77.
198. Middel B, van Sonderen E. Statistical significant change versus relevant or important change in (quasi) experimental design: some conceptual and methodological problems in estimating magnitude of intervention-related change in health services research. *Int J Integr Care*. 2002;2:e15.
199. Florian A, Ludwig A, Engelen M, Waltenberger J, Rosch S, Sechtem U, et al. Left ventricular systolic function and the pattern of late-gadolinium-enhancement independently and additively predict adverse cardiac events in muscular dystrophy patients. *J Cardiovasc Magn Reson*. 2014;16:81.
200. Kaspar RW, Allen HD, Ray WC, Alvarez CE, Kissel JT, Pestronk A, et al. Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in becker muscular dystrophy. *Circ Cardiovasc Genet*. 2009;2(6):544-51.
201. Marty B, Gilles R, Toussaint M, Behin A, Stojkovic T, Eymard B, et al. Comprehensive evaluation of structural and functional myocardial impairments in Becker muscular dystrophy using quantitative cardiac magnetic resonance imaging. *Eur Heart J Cardiovasc Imaging*. 2019;20(8):906-15.
202. Schmach L, Traber J, Grieben U, Utz W, Dieringer MA, Kellman P, et al. Cardiac Involvement in Myotonic Dystrophy Type 2 Patients With Preserved Ejection Fraction: Detection by Cardiovascular Magnetic Resonance. *Circ Cardiovasc Imaging*. 2016;9(7).
203. Blaszczyk E, Grieben U, von Knobelsdorff-Brenkenhoff F, Kellman P, Schmach L, Funk S, et al. Subclinical myocardial injury in patients with Facioscapulohumeral muscular dystrophy 1 and preserved ejection fraction - assessment by cardiovascular magnetic resonance. *J Cardiovasc Magn Reson*. 2019;21(1):25.
204. Park SJ, Cho SW, Kim SM, Ahn J, Carriere K, Jeong DS, et al. Assessment of Myocardial Fibrosis Using Multimodality Imaging in Severe Aortic Stenosis: Comparison With Histologic Fibrosis. *JACC Cardiovascular imaging*. 2019;12(1):109-19.
205. Almaas VM, Haugaa KH, Strom EH, Scott H, Smith HJ, Dahl CP, et al. Noninvasive assessment of myocardial fibrosis in patients with obstructive hypertrophic cardiomyopathy. *Heart*. 2014;100(8):631-8.

206. Silva MC, Magalhaes TA, Meira ZM, Rassi CH, Andrade AC, Gutierrez PS, et al. Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial. *JAMA Cardiol.* 2017;2(2):190-9.
207. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Becane HM. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. *J Am Coll Cardiol.* 2005;45(6):855-7.
208. Schade van Westrum S, Dekker L, de Haan R, Endert E, Ginjaar I, de Visser M, et al. Brain natriuretic peptide is not predictive of dilated cardiomyopathy in Becker and Duchenne muscular dystrophy patients and carriers. *BMC Neurol.* 2013;13:88.
209. Wilkins MR, Redondo J, Brown LA. The natriuretic-peptide family. *Lancet.* 1997;349(9061):1307-10.
210. Flanigan KM, Dunn DM, von Niederhausern A, Soltanzadeh P, Howard MT, Sampson JB, et al. Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene. *Hum Mutat.* 2011;32(3):299-308.
211. Bushby KM, Thambyayah M, Gardner-Medwin D. Prevalence and incidence of Becker muscular dystrophy. *Lancet.* 1991;337(8748):1022-4.
212. Comi GP, Prelle A, Bresolin N, Moggio M, Bardoni A, Gallanti A, et al. Clinical variability in Becker muscular dystrophy. Genetic, biochemical and immunohistochemical correlates. *Brain.* 1994;117 (Pt 1):1-14.
213. Ferlini A, Flanigan KM, Lochmuller H, Muntoni F, t Hoen PA, McNally E. 204th ENMC International Workshop on Biomarkers in Duchenne Muscular Dystrophy 24-26 January 2014, Naarden, The Netherlands. *Neuromuscul Disord.* 2015;25(2):184-98.
214. Kerr KF, Roth J, Zhu K, Thiessen-Philbrook H, Meisner A, Wilson FP, et al. Evaluating biomarkers for prognostic enrichment of clinical trials. *Clin Trials.* 2017;14(6):629-38.
215. Ayoglu B, Chaouch A, Lochmuller H, Politano L, Bertini E, Spitali P, et al. Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies. *EMBO Mol Med.* 2014;6(7):918-36.
216. Hathout Y, Marathi RL, Rayavarapu S, Zhang A, Brown KJ, Seol H, et al. Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. *Human molecular genetics.* 2014;23(24):6458-69.
217. Capitanio D, Moriggi M, Torretta E, Barbacini P, De Palma S, Vigano A, et al. Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients. *J Cachexia Sarcopenia Muscle.* 2020;11(2):547-63.
218. Burch PM, Pogoryelova O, Goldstein R, Bennett D, Guglieri M, Straub V, et al. Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy. *J Neuromuscul Dis.* 2015;2(3):241-55.
219. Strandberg K, Ayoglu B, Roos A, Reza M, Niks E, Signorelli M, et al. Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy. *J Neuromuscul Dis.* 2020;7(3):231-46.

REFERENCES

220. Signorelli M, Ayoglu B, Johansson C, Lochmuller H, Straub V, Muntoni F, et al. Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy. *J Cachexia Sarcopenia Muscle*. 2020;11(2):505-17.
221. Barp A, Ferrero A, Casagrande S, Morini R, Zuccarino R. Circulating Biomarkers in Neuromuscular Disorders: What Is Known, What Is New. *Biomolecules*. 2021;11(8).
222. McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. *Proc Natl Acad Sci U S A*. 1997;94(23):12457-61.
223. Bodamer OA, Bloesch SM, Gregg AR, Stockler-Ipsiroglu S, O'Brien WE. Analysis of guanidinoacetate and creatine by isotope dilution electrospray tandem mass spectrometry. *Clin Chim Acta*. 2001;308(1-2):173-8.
224. Koeks Z, Janson AA, Beekman C, Signorelli M, van Duyvenvoorde HA, van den Bergen JC, et al. Low dystrophin variability between muscles and stable expression over time in Becker muscular dystrophy using capillary Western immunoassay. *Sci Rep*. 2021;11(1):5952.
225. van den Bergen JC, Wokke BH, Janson AA, van Duinen SG, Hulsker MA, Ginjaar HB, et al. Dystrophin levels and clinical severity in Becker muscular dystrophy patients. *Journal of neurology, neurosurgery, and psychiatry*. 2014;85(7):747-53.
226. McCulloch CE, Searle SR. *Generalized, linear, and mixed models*: John Wiley & Sons; 2004.
227. Kuznetsova A, Brockhoff PB, Christensen RH. lmerTest package: tests in linear mixed effects models. *Journal of Statistical Software*. 2017;82(1):1-26.
228. Benjamini Y, Hockberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society: Series B (Methodological)*. 1995;57(1):289-300.
229. Efron B. Estimating the error rate of a prediction rule: improvement on cross-validation. *Journal of the American Statistical Association*. 1983;78(382):316-31.
230. U.S. Department of Health and Human Services Food and Drug Administration. *Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry 2018* [Available from: <https://www.fda.gov/media/92233/download>].
231. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. *Physiol Rev*. 2000;80(3):1107-213.
232. Walker JB. Creatine: biosynthesis, regulation, and function. *Adv Enzymol Relat Areas Mol Biol*. 1979;50:177-242.
233. Wang L, Xu M, Liu D, Liang Y, Feng P, Li H, et al. Serum creatinine as a biomarker for dystrophinopathy: a cross-sectional and longitudinal study. *BMC Neurol*. 2021;21(1):372.
234. Zhang H, Zhu Y, Sun Y, Liang Y, Li Y, Zhang Y, et al. Serum creatinine level: a supplemental index to distinguish Duchenne muscular dystrophy from Becker muscular dystrophy. *Dis Markers*. 2015;2015:141856.

235. Alves CRR, Zhang R, Johnstone AJ, Garner R, Nwe PH, Siranosian JJ, et al. Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy. *Neurology*. 2020;94(9):e921-e31.
236. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. *Nature*. 1997;387(6628):83-90.
237. Lee SJ. Extracellular Regulation of Myostatin: A Molecular Rheostat for Muscle Mass. *Immunol Endocr Metab Agents Med Chem*. 2010;10:183-94.
238. Elkina Y, von Haehling S, Anker SD, Springer J. The role of myostatin in muscle wasting: an overview. *J Cachexia Sarcopenia Muscle*. 2011;2(3):143-51.
239. Dumonceaux J, Marie S, Beley C, Trollet C, Vignaud A, Ferry A, et al. Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice. *Mol Ther*. 2010;18(5):881-7.
240. Lee YS, Lehar A, Sebald S, Liu M, Swaggart KA, Talbot CC, Jr., et al. Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy. *Human molecular genetics*. 2015;24(20):5711-9.
241. Harish P, Malerba A, Lu-Nguyen N, Forrest L, Cappellari O, Roth F, et al. Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD). *J Cachexia Sarcopenia Muscle*. 2019;10(5):1016-26.
242. Wagner KR, McPherron AC, Winik N, Lee SJ. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. *Ann Neurol*. 2002;52(6):832-6.
243. Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med*. 2002;166(1):111-7.
244. Goemans N, Wong B, Van den Hauwe M, Signorovitch J, Sajeev G, Cox D, et al. Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration. *PLoS One*. 2020;15(6):e0232870.
245. Larkindale J, Kim S, Lingineni K, Schmidt S, Corey D, Romero K. Development of a Regulatory-Ready Clinical Trial Simulation Tool for Duchenne Muscular Dystrophy. 2020 [Available from: https://c-path.org/wp-content/uploads/2021/04/Development-of-a-regulatory-ready-clinical-trial-simulation-tool-for-Duchenne-muscular-dystrophy_Abstract_WMS_2020.pdf].
246. Beggs AH, Hoffman EP, Snyder JR, Arahata K, Specht L, Shapiro F, et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. *Am J Hum Genet*. 1991;49(1):54-67.
247. Bello L, Campadello P, Barp A, Fanin M, Semplicini C, Soraru G, et al. Functional changes in Becker muscular dystrophy: implications for clinical trials in dystrophinopathies. *Sci Rep*. 2016;6:32439.
248. van de Velde NM, Hooijmans MT, Sardjoe Mishre ASD, Keene KR, Koeks Z, Veeger TTJ, et al. Selection Approach to Identify the Optimal Biomarker Using Quantitative Muscle MRI and Functional Assessments in Becker Muscular Dystrophy. *Neurology*. 2021;97(5):e513-e22.

249. Straub V, Balabanov P, Bushby K, Ensini M, Goemans N, De Luca A, et al. Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. *Lancet Neurol.* 2016;15(8):882-90.
250. Barnard AM, Willcocks RJ, Triplett WT, Forbes SC, Daniels MJ, Chakraborty S, et al. MR biomarkers predict clinical function in Duchenne muscular dystrophy. *Neurology.* 2020;94(9):e897-e909.
251. Murphy AP, Morrow J, Dahlqvist JR, Stojkovic T, Willis TA, Sinclair CDJ, et al. Natural history of limb girdle muscular dystrophy R9 over 6 years: searching for trial endpoints. *Ann Clin Transl Neurol.* 2019;6(6):1033-45.
252. Gidaro T, Reyngoudt H, Le Louer J, Behin A, Toumi F, Villeret M, et al. Quantitative nuclear magnetic resonance imaging detects subclinical changes over 1 year in skeletal muscle of GNE myopathy. *J Neurol.* 2020;267(1):228-38.
253. Maggi L, Moscatelli M, Frangiamore R, Mazzi F, Verri M, De Luca A, et al. Quantitative Muscle MRI Protocol as Possible Biomarker in Becker Muscular Dystrophy. *Clin Neuroradiol.* 2020.
254. Wokke BH, van den Bergen JC, Versluis MJ, Niks EH, Milles J, Webb AG, et al. Quantitative MRI and strength measurements in the assessment of muscle quality in Duchenne muscular dystrophy. *Neuromuscular disorders : NMD.* 2014;24(5):409-16.
255. Hooijmans MT, Froeling M, Koeks Z, Verschuuren J, Webb A, Niks EH, et al. Multi-parametric MR in Becker muscular dystrophy patients. *NMR Biomed.* 2020:e4385.
256. Akima H, Lott D, Senesac C, Deol J, Germain S, Arpan I, et al. Relationships of thigh muscle contractile and non-contractile tissue with function, strength, and age in boys with Duchenne muscular dystrophy. *Neuromuscular disorders : NMD.* 2012;22(1):16-25.
257. Cohen J. *Statistical power analysis for the behavioral sciences.* : Hillsdale, N.J. Erlbaum Associates. ; 1988.
258. The natural history study of Becker muscular dystrophy [NL50171.058.14]. Available from: https://www.toetsingonline.nl/to/ccmo_search.nsf/fABRpop?readform&unids=98B27357A2A7F7FC12585A500153A22.
259. Andersen G, Dahlqvist JR, Vissing CR, Heje K, Thomsen C, Vissing J. MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients. *J Neurol.* 2017;264(3):438-47.
260. Nunez-Peralta C, Alonso-Perez J, Llauger J, Segovia S, Montesinos P, Belmonte I, et al. Follow-up of late-onset Pompe disease patients with muscle magnetic resonance imaging reveals increase in fat replacement in skeletal muscles. *J Cachexia Sarcopenia Muscle.* 2020.
261. Heskamp L, van Nimwegen M, Ploegmakers MJ, Bassez G, Deux JF, Cumming SA, et al. Lower extremity muscle pathology in myotonic dystrophy type 1 assessed by quantitative MRI. *Neurology.* 2019;92(24):e2803-e14.
262. Mul K, Vincenten SCC, Voermans NC, Lemmers R, van der Vliet PJ, van der Maarel SM, et al. Adding quantitative muscle MRI to the FSHD clinical trial toolbox. *Neurology.* 2017;89(20):2057-65.

263. Reyngoudt H, Marty B, Boisserie JM, Le Louer J, Koumako C, Baudin PY, et al. Global versus individual muscle segmentation to assess quantitative MRI-based fat fraction changes in neuromuscular diseases. *Eur Radiol*. 2020.
264. Hooijmans MT, Niks EH, Burakiewicz J, Anastasopoulos C, van den Berg SI, van Zwet E, et al. Non-uniform muscle fat replacement along the proximodistal axis in Duchenne muscular dystrophy. *Neuromuscul Disord*. 2017;27(5):458-64.
265. Chrzanowski SM, Baligand C, Willcocks RJ, Deol J, Schmalfluss I, Lott DJ, et al. Multi-slice MRI reveals heterogeneity in disease distribution along the length of muscle in Duchenne muscular dystrophy. *Acta Myol*. 2017;36(3):151-62.
266. Janssen BH, Voet NB, Nabuurs CI, Kan HE, de Rooy JW, Geurts AC, et al. Distinct disease phases in muscles of facioscapulohumeral dystrophy patients identified by MR detected fat infiltration. *PLoS One*. 2014;9(1):e85416.
267. Schlaffke L, Rehmann R, Rohm M, Otto LAM, de Luca A, Burakiewicz J, et al. Multi-center evaluation of stability and reproducibility of quantitative MRI measures in healthy calf muscles. *NMR Biomed*. 2019;32(9):e4119.
268. Hu HH, Yokoo T, Bashir MR, Sirlin CB, Hernando D, Malyarenko D, et al. Linearity and Bias of Proton Density Fat Fraction as a Quantitative Imaging Biomarker: A Multicenter, Multiplatform, Multivendor Phantom Study. *Radiology*. 2021;298(3):640-51.
269. Kugathasan U, Evans MRB, Morrow JM, Sinclair CDJ, Thornton JS, Yousry TA, et al. Development of MRC Centre MRI calf muscle fat fraction protocol as a sensitive outcome measure in Hereditary Sensory Neuropathy Type 1. *J Neurol Neurosurg Psychiatry*. 2019;90(8):895-906.
270. Willcocks RJ, Arpan IA, Forbes SC, Lott DJ, Senesac CR, Senesac E, et al. Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression. *Neuromuscular disorders : NMD*. 2014;24(5):393-401.
271. Hooijmans MT, Niks EH, Burakiewicz J, Verschuuren JJ, Webb AG, Kan HE. Elevated phosphodiester and T2 levels can be measured in the absence of fat infiltration in Duchenne muscular dystrophy patients. *NMR Biomed*. 2017;30(1).
272. Plant D, Barton A. Adding value to real-world data: the role of biomarkers. *Rheumatology (Oxford)*. 2020;59(1):31-8.
273. Lee E, Moon A. Identification of Biomarkers for Breast Cancer Using Databases. *J Cancer Prev*. 2016;21(4):235-42.
274. Mercuri E, Osorio AN, Muntoni F, Buccella F, Desguerre I, Kirschner J, et al. Correction to: Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015-2022): 2022 interim analysis. *J Neurol*. 2023.
275. U.S. Department of Health and Human Services - Food and Drug Administration. FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy 2024 [Available from: <https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy>].

276. Amedro P, Vincenti M, De La Villeon G, Lavastre K, Barrea C, Guillaumont S, et al. Speckle-Tracking Echocardiography in Children With Duchenne Muscular Dystrophy: A Prospective Multicenter Controlled Cross-Sectional Study. *J Am Soc Echocardiogr*. 2019;32(3):412-22.
277. Akyuz A, Cap M, Varsak S, Isik F, Turken A, Tastan E, et al. Evaluation of cardiomyopathy with two-dimensional speckle tracking echocardiography in limb-girdle muscular dystrophy type 2A and 2B. *J Clin Ultrasound*. 2022;50(9):1242-8.
278. Petri H, Witting N, Ersboll MK, Sajadieh A, Duno M, Helweg-Larsen S, et al. High prevalence of cardiac involvement in patients with myotonic dystrophy type 1: a cross-sectional study. *International journal of cardiology*. 2014;174(1):31-6.
279. Stalens C, Motte L, Behin A, Ben Yaou R, Leturcq F, Bassez G, et al. Improved Cardiac Outcomes by Early Treatment with Angiotensin-Converting Enzyme Inhibitors in Becker Muscular Dystrophy. *J Neuromuscul Dis*. 2021;8(4):495-502.
280. Porcher R, Desguerre I, Amthor H, Chabrol B, Audic F, Rivier F, et al. Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy-analysis of registry data. *European heart journal*. 2021;42(20):1976-84.
281. Kammerlander AA. Feature Tracking by Cardiovascular Magnetic Resonance Imaging: The New Gold Standard for Systolic Function? *JACC Cardiovascular imaging*. 2020;13(4):948-50.
282. Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. *Heart*. 2014;100(21):1673-80.
283. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Crespo Leiro M, Drozd J, et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). *European journal of heart failure*. 2013;15(7):808-17.
284. Almogheer B, Antonopoulos AS, Azzu A, Al Mohdar S, Vlachopoulos C, Pantazis A, et al. Diagnostic and Prognostic Value of Cardiovascular Magnetic Resonance in Neuromuscular Cardiomyopathies. *Pediatr Cardiol*. 2022;43(1):27-38.
285. Kerstens TP, van Everdingen WM, Habets J, van Dijk APJ, Helbing WA, Thijssen DHJ, et al. Left ventricular deformation and myocardial fibrosis in pediatric patients with Duchenne muscular dystrophy. *International journal of cardiology*. 2023:131162.
286. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *European heart journal*. 2021;42(36):3599-726.
287. Henson SE, Lang SM, Khoury PR, Tian C, Rutter MM, Urbina EM, et al. The Effect of Adiposity on Cardiovascular Function and Myocardial Fibrosis in Patients With Duchenne Muscular Dystrophy. *J Am Heart Assoc*. 2021;10(19):e021037.
288. Marozzo R, Pegoraro V, Angelini C. MiRNAs, Myostatin, and Muscle MRI Imaging as Biomarkers of Clinical Features in Becker Muscular Dystrophy. *Diagnostics (Basel)*. 2020;10(9).

289. Su XW, Simmons Z, Mitchell RM, Kong L, Stephens HE, Connor JR. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis. *JAMA Neurol.* 2013;70(12):1505-11.
290. Fledrich R, Mannil M, Leha A, Ehbrecht C, Solari A, Pelayo-Negro AL, et al. Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A. *Journal of neurology, neurosurgery, and psychiatry.* 2017;88(11):941-52.
291. Schmidt S, Hafner P, Klein A, Rubino-Nacht D, Gocheva V, Schroeder J, et al. Timed function tests, motor function measure, and quantitative thigh muscle MRI in ambulant children with Duchenne muscular dystrophy: A cross-sectional analysis. *Neuromuscular disorders : NMD.* 2018;28(1):16-23.
292. Arrigoni F, De Luca A, Velardo D, Magri F, Gandossini S, Russo A, et al. Multiparametric quantitative MRI assessment of thigh muscles in limb-girdle muscular dystrophy 2A and 2B. *Muscle & nerve.* 2018;58(4):550-8.
293. Reyngoudt H, Marty B, Boiserie JM, Le Louer J, Koumako C, Baudin PY, et al. Global versus individual muscle segmentation to assess quantitative MRI-based fat fraction changes in neuromuscular diseases. *Eur Radiol.* 2021;31(6):4264-76.
294. Rooney WD, Berlow YA, Triplett WT, Forbes SC, Willcocks RJ, Wang DJ, et al. Modeling disease trajectory in Duchenne muscular dystrophy. *Neurology.* 2020;94(15):e1622-e33.
295. Hooijmans MT, Doorenweerd N, Baligand C, Verschuuren J, Ronen I, Niks EH, et al. Spatially localized phosphorous metabolism of skeletal muscle in Duchenne muscular dystrophy patients: 24-month follow-up. *PLoS One.* 2017;12(8):e0182086.
296. Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D, et al. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis. *JAMA Cardiol.* 2019;4(10):1007-18.
297. Clemens PR, Niizawa G, Feng J, Florence J, D'Alessandro AS, Morgenroth LP, et al. The CINRG Becker Natural History Study: Baseline characteristics. *Muscle Nerve.* 2020;62(3):369-76.
298. Ricci G, Govoni A, Torri F, Astrea G, Buchignani B, Marinella G, et al. Characterization of Phenotypic Variability in Becker Muscular Dystrophy for Clinical Practice and Towards Trial Readiness: A Two-Years Follow up Study. *J Neuromuscul Dis.* 2024;11(2):375-87.
299. Nakamura A, Matsumura T, Ogata K, Mori-Yoshimura M, Takeshita E, Kimura K, et al. Natural history of Becker muscular dystrophy: a multicenter study of 225 patients. *Ann Clin Transl Neurol.* 2023;10(12):2360-72.